Adicet Bio, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. Adicet is a clinical-stage biotechnology company developing allogeneic gamma delta T-cell cancer therapies. It had no approved products and no product-sales revenue; reported revenue was from its Regeneron collaboration.
Key financial results
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue, related party | $25.0 million | $(4.0) million |
| Research and development expense | $13.5 million | $11.7 million |
| General and administrative expense | $6.8 million | $5.6 million |
| Total operating expenses | $20.3 million | $17.4 million |
| Operating income (loss) | $4.7 million | $(21.4) million |
| Net income (loss) | $4.6 million | $(21.3) million |
| Operating cash flow | $4.1 million | $(15.1) million |
Revenue was $25.0 million, including a $20.0 million Regeneron option-exercise payment for ADI-002; the remaining collaboration performance obligations were completed during the quarter. The resulting profit and positive operating cash flow are therefore not evidence of recurring product revenue. Operating margin was approximately 18.8%, but is materially affected by collaboration revenue and is not a representative product margin.
At March 31, cash and cash equivalents were $277.9 million, with an additional $0.15 million of restricted cash. Total assets were $340.5 million, total liabilities $29.4 million, and stockholders’ equity $311.1 million. The company reported no outstanding term-loan debt; $4.4 million of ancillary banking services were outstanding and $10.6 million remained available under the PacWest facility. Operating lease liabilities totaled $20.6 million.
Changes versus prior comparable period
- Revenue increased by $29.0 million from a negative $4.0 million in Q1 2021, principally reflecting the $20.0 million ADI-002 option fee and completion of the Regeneron collaboration obligations. Q1 2021 revenue included a $4.0 million cumulative revenue reduction following a change in cost estimates.
- Net results improved from a $21.3 million loss to $4.6 million of income. The company states that this quarter’s income was primarily driven by the Regeneron milestone payment.
- R&D expense increased 15% to $13.5 million, mainly from higher personnel, laboratory, manufacturing and facility costs. G&A increased 21% to $6.8 million, primarily due to headcount and stock-based compensation.
- Operating cash flow improved from $15.1 million used to $4.1 million provided. Cash increased only $0.3 million during the quarter, as capital spending and equity-award tax withholding offset much of the operating inflow.
Outlook, developments and risks
- Management expected existing cash to fund forecast operating expenses, capital expenditures and debt service for at least 12 months from issuance of the financial statements. Elsewhere, the risk discussion estimated funding into the second half of 2024, while cautioning that assumptions may prove wrong and further capital will be needed.
- ADI-001 was in a Phase 1 study for non-Hodgkin lymphoma (NHL). The company expected to report updated interim data at ASCO on June 6, 2022; the FDA granted Fast Track Designation in April 2022. These are forward-looking or subsequent-period developments, not Q1 financial results.
- Regeneron exercised its option for ADI-002, a GPC3-targeted therapy, paid $20.0 million, and assumed responsibility for its development, manufacturing and commercialization. Adicet declined its co-funding option and is eligible for high-single-digit royalties on potential future net sales.
- The company increased the Redwood City construction budget by approximately $5.3 million to add GMP cell-processing and vector-manufacturing suites and controlled-materials warehousing. Construction-in-progress reached $16.3 million; completion was expected in Q3 2022.
- Key risks include early-stage clinical and regulatory uncertainty, reliance on third-party manufacturers and suppliers, funding needs, trial enrollment and COVID-19 disruption, and potential supply interruptions related to the Russia–Ukraine conflict. Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. No material legal proceedings were reported.
Investor verification priorities
- Confirm the composition and nonrecurring nature of Q1 revenue, including the $20.0 million ADI-002 fee and the final recognition of Regeneron collaboration revenue.
- Track ADI-001 Phase 1 safety, efficacy, enrollment and subsequent data; verify the timing and substance of any reported updates.
- Reconcile the stated cash runway estimates and monitor cash burn, planned capital spending, and the need and terms of future financing.
- Monitor Redwood City facility costs, completion timing and whether the new suites support planned manufacturing needs.
- Assess reliance on Regeneron and external manufacturers, supplier availability, and any changes to collaboration, royalty or license arrangements.